Public Perception Survey
The Future of Peptides and Hormones in U.S. Medicine
Context Statement (Intro for Respondents)
Recent policy signals — including public discussion about expanding access to certain peptides — have sparked debate about the future role of peptide and hormone-based therapies in preventive care, metabolic medicine, performance optimization, and longevity.
This survey explores how informed healthcare consumers perceive the future clinical adoption, safety, accessibility, and societal impact of peptide and hormone therapies.
Response Scale (Use for all statements)
1 — Strongly Disagree
2 — Disagree
3 — Neutral / Unsure
4 — Agree
5 — Strongly Agree
Expanding access to peptides will accelerate innovation in metabolic and preventive medicine.
The healthcare system is not yet prepared to safely manage widespread peptide adoption.
Physician-led oversight should remain mandatory for peptide therapy access.
Insurance coverage will eventually expand to include certain peptide therapies.
Peptides will become a mainstream part of medical weight-loss protocols.
Primary care physicians will increasingly prescribe peptides in the next 5 years.
Telemedicine will be the dominant delivery model for peptide therapy access.
Rapid peptide adoption could lead to misuse or over-commercialization.
Social media is shaping unrealistic expectations about peptide outcomes.
Clinical evidence for many peptides remains insufficient for widespread use.
GLP-1–based therapies will see massive growth in use over the next 5 years.
Musculoskeletal recovery peptides (e.g., BPC-157 / TB-500) will see major demand growth.
Longevity-focused peptides will become a major healthcare trend.
Hormone optimization therapies will become increasingly normalized.
I would consider peptide therapy if supervised by a physician.
Peptides will meaningfully reduce rates of metabolic disease.
